Discovery of novel RIPK3 inhibitors by virtual screening and bioactivity evaluation.
An integrated virtual screening strategy based on molecular fingerprint similarity, pharmacophore models, molecular docking, and molecular dynamics simulation is proposed and three promising lead compounds targeting RIPK3 for AD treatment are offered.